Neuropeptide Y (NPY) is a ubiquitous peptide with multiple effects on energy metabolism, reproduction, neurogenesis, and emotion. In addition, NPY is an important sympathetic neurotransmitter involved in neurovascular regulation. While early studies suggested that the vasoactive effects of NPY were limited to periods of high stress, there is growing evidence for the involvement of NPY on baseline vasomotor tone and sympathetically evoked vasoconstriction in vivo in both skeletal muscle and the cutaneous circulation. In SpragueDawley rat skeletal muscle, Y 1 -receptor activation appears to play an important role in the regulation of basal vascular conductance and this effect is similar in magnitude to the α 1 -receptor contribution. Furthermore, under baseline conditions, agonist and receptor-based mechanisms for Y 1 -receptor dependent control of vascular conductance in skeletal muscle are greater in male than female rats. In skin, there is Y 1 -receptor-mediated vasoconstriction during whole-body, but not local, cooling. As with the NPY system in muscle, this neural effect in skin differs between males and females and in addition, declines with aging. Intriguingly, skin vasodilation to local heating also requires NPY, and is currently thought to be acting via a nitric oxide pathway.
Introduction
Skeletal muscle and skin represent two organs that are under strong sympathetic neurogenic vasomotor control, a neural mechanism that contributes to the large range of vascular conductance in these tissues. Historically, emphasis has been placed on the purinergic and adrenergic (norepinephrine; NE) neurotransmitters and receptor mechanisms mediating neurovascular control in these beds. However, advances in the pharmacology of neuropeptide Y (NPY) and the Y-receptor family over the past two decades have enabled direct examination of the role of Y-receptor mechanisms influencing sympathetic neurogenic vasomotor control. NPY and Y-receptors are ubiquitous and involved in many neurogenic functions ranging from cortical actions in satiety and emotion, to blood flow distribution in the periphery. Determining a role of this neurotransmitter in vasomotor control has been challenging as its effects appear to vary from tissue to tissue and with sex hormones. NPY and its receptors have been reported to be present in all the major tissues of the body and implicated in numerous processes; however, in this review, we limit our discussion to: 1) NPY and the Y 1 -receptor (Y 1 R) and Y 2 -receptors (Y 2 R) involved in vasomotor control, 2) the concept of frequency-dependent neuronal release of NPY and/or Y 1 R activation, 3) sexual dimorphism in the NPY-Y 1 R control system, and 4) recent evidence regarding a role for this system in the control of blood flow in skeletal muscle and skin.
Neuropeptide Y structure and synthesis NPY, first isolated from the porcine brain (99) , is a 36 amino acid residue member of a family of peptides that includes pancreatic polypeptide and peptide YY. Its name derives from the tyrosine residues located at both the N-and C-terminal ends, as well as the relatively high tyrosine content of the complete NPY molecule. Biologically active NPY is derived from a 97-amino acid precursor, pre-pro-neuropeptide Y. NPY is formed following four posttranslational enzymatic reactions (42) , the first of which results in the 69 amino acid residue proNPY after the removal of the signal sequence by signal peptidase. Subsequently, proNPY is broken down by prohormone convertase PC2 and/or PC1/3 at the paired basic site Lys 38 -Arg 39 , in turn releasing the 30 amino acid C-flanking peptide of NPY and NPY (78) . A carboxypeptidase-like enzyme further processes NPY , resulting in NPY which becomes amidated at its C-terminal end by peptidyl-glycine-α-amidating monooxygenase that cleaves another amino acid. The resulting fragment, NPY , is referred to as biologically active NPY or simply NPY.
NPY is co-released with NE from within peripheral sympathetic nerves that supply blood vessels. Specifically, it is proposed that NE is contained and released from small dense cored vesicles whereas NPY is contained within large dense cored vesicles. This hypothesis predicts that NE primarily controls vascular smooth muscle tone during basal conditions whereas NPY should not, its release only occurring during periods of high stress. Although some debate remains, pharmacological and physiological studies support the differential release of NPY and NE (57, 63) .The discovery of the physiological potential of NPY in blood vessels originated from experiments on the feline submandibular gland where, after sympathetic nerve stimulation, slow and persisting α-adrenergic independent vasoconstriction was observed (66) . Anatomical evidence confirms that, in peripheral tissues, nerve fibers that contain NPY are more abundant around resistance vessels with increasing density as vessel size decreases (98) .
The neuropeptide Y Y 1 -receptor
The NPY Y 1 R, first of the Y-receptors cloned, was originally recognized in the rat brain (31), and cloned soon after from human transfected cells (41, 59) . 
Interaction between neuropeptide Y and norepinephrine
Sympathetic postganglionic neurons in rat tail artery and guinea-pig vas deferens release NE, NPY, and ATP (11, 53) , with release of these contents being more prevalent at high nerve stimulation frequencies (11, 63) . ATP and NPY provide significant contributions to rat tail vascular tone, especially at higher impulse frequencies (11) . This cocktail of neurochemical messengers enables a number of biological effects and interactions (e.g. slow, intermediary, and rapid signalling) (62) . NPY potentiates α-adrenergic vasoconstriction in both in vivo (17, 60, 89) and in vitro (11, , 27, 28, 36, 105) preparations. The synergistic interaction between NPY and NE is receptormediated. Thus, NPY enhances the vasoconstrictor response to both sympathetic nerve stimulation (11, 17) and phenylephrine-(specific α 1 R agonist) induced vasoconstriction (17) .
The likely mechanism responsible for the synergistic effects of NPY and NE is the convergence of second messenger signalling pathways acting through phospholipase C resulting in protein kinase C activation (109) . Also NPY transiently increases myosin light chain phosphorylation (61) an effect that would augument contraction. This is consistent with the known ability of NPY to potentiate NE-mediated vasoconstriction and inhibition of vasorelaxation. Thus, the interactive effects must be due to consequent modification of specific receptor properties and/or second messengers (33).
Role of neuropeptide Y in the regulation of vasomotor tone

General Background
A major issue regarding the involvement of NPY in neurovascular regulation in muscle has been the uncertainty regarding a role of this neurotransmitter under baseline (resting) conditions.
These concerns are particularly important in regard to the controversies surrounding any impact of NPY on baseline blood pressure, as well as with the hypotheses regarding the mechanistic role of sympathetic neurotransmitters in cardiovascular tissue damage during periods of chronically heightened sympathetic discharge with advancing age and disease. Tese issues are complicated further by variations of NPY composition that may heighten any detrimental aspects of this neurotransmitter. For example, the leucine7 to proline7 polymorphism in NPY has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases (46) .
NPY, blood pressure, and sympathetic discharge
As mentioned above, the role of NPY in blood pressure regulation is debated. Evidence from Y 1 R knockout mice that display normal basal blood pressure (86) suggests that NPY does not play a critical role in blood pressure maintenance. Moreover, infusion of the Y 1 R antagonist BIBP3226 does not affect basal blood pressure in normotensive or in spontaneously hypertensive rats (which have elevated plasma NPY levels) (111) . Consequently, a role for NPY as a regulator of baseline vascular control has been discounted. Nonetheless, circulating NPY levels rise during circulatory shock, chronic stress (e.g., sepsis, haemorrhage, cold stress) (88, 115), and even heavy exercise (64, 75) . Thus, it may be that NPY release is related to discharge frequencies of the postganglionic sympathetic neurons and play a more important role in blood pressure regulation in times of significant stress.
Additional evidence in support of the idea that NPY is released primarily during periods of high sympathetic outflow comes from studies of sympathetic activity and vascular disease. Although the sympathetic nervous system is critical for maintaining blood flow/pressure homeostasis during acute stress (e.g., during exercise, cold exposure, or orthostatic stress), several investigations indicate that this nervous system is also involved in long-term vascular control and/or morphological changes in vascular structure. For example, a relationship is described between essential hypertension and chronically augmented sympathetic nerve activity and its association with increased vascular resistance (72), intimal wall thickness (23) and damage to cardiovascular tissues (30, 54, 85, 110) . These deleterious effects of sympathetic outflow appear to include the dual actions of the sympathetic neurotransmitters NE (e.g. 38) and NPY (58) acting on post-junctional α-and Y-receptors, respectively. In this regard, NPY has been implicated in hypertension (77) as there are high circulating levels of NPY present in both men and women with the disease (107) . Moreover, the mitogenic potential of NPY has been established (87, 91, 112, 113) . These data suggest that NPY release is dependent upon the magnitude of nerve discharge frequency; thus, elevated sympathetic nerve activity may lead to increased mitogenesis via the actions of NPY. Nonetheless, Y 1 R activation must occur chronically under baseline conditions if it is to factor importantly in long-term blood pressure regulation, and/or mitogenic effects. Chronic basal Y 1 R activation, however, has not been demonstrated with certainty as outlined above.
The evidence that NPY does not affect baseline blood pressure, but is released during periods of high stress, suggests that NE and NPY are differentially released (4, 18, 63) with NE released at lower nerve activity and NPY released only under high neuronal stimulation frequencies. This hypothesis predicts that NE primarily controls vascular smooth muscle tone during basal conditions whereas NPY does not; its release only occurring during periods of high stress.
Pharmacological and physiological studies support the differential release of NPY and NE (57, 63) . 
NPY and vasomotor control in skeletal muscle
Skeletal muscle represents 30-40% of body mass and is under considerable neurogenic and metabolic control that enables blood flow changes that are rapid and large in magnitude, ranging from 5 ml · 100 ml -1 · min -1 to at least 250 ml · 100ml -1 · min -1 (1) . This translates to skeletal muscle receiving up to 85 to 90 % of maximal cardiac output during extended periods of exercise 
Sex-dependent NPY neurovascular control in skeletal muscle
Several lines of evidence support the conclusion that gender affects neurovascular control. In human studies, females have on average, lower levels of baseline (52, 84) and reflex-mediated changes in muscle sympathetic nerve activity (92) . Similar studies on baseline sympathetic levels 
Involvement of NPY in the regulation of skin blood flow
General Background
Skin blood flow (SkBF) in humans is controlled through two branches of the sympathetic nervous system: a vasoconstrictor system and an active vasodilator system of uncertain neurotransmitter (50) . The vasodilator system is not tonically active but is engaged during periods of increased internal temperature (50) . Previous studies suggest this system to be cholinergic and to involve a cotransmitter, possibly vasoactive intestinal peptide (VIP) (5, 56) . In contrast, the vasoconstrictor system is tonically active, mediating the subtle changes in SkBF required to maintain internal temperature in normothermia (12) (Figure 2 ). These data support the notion that, at least in skin under these particular conditions, NPY acts independently of NE to elicit vasoconstriction. In contrast to the above studies using whole-body cooling, the involvement of NPY in the vasoconstrictor response to local cooling was minimal (51). Thus, it appears that NPY-induced cutaneous vasoconstriction requires a stress-induced increase in sympathetic nerve activity that would occur with systemic cooling but not local cooling.
NPY and vasomotor control in the cutaneous circulation
In Though it is somewhat counter-intuitive that adrenergic nerve transmitters should promote the vasodilator response, there are data that show NE and NPY bind to α 2 R and Y 1 R on endothelial cells and stimulate endothelial nitric oxide synthase, leading to the production of nitric oxide (2, 15, 104) . In keeping with this possibility, we also tested whether the effects of NE and NPY on cutaneous vasodilation were dependent on nitric oxide synthase function (43) . We observed that the heat-induced vasodilation was abolished with both presynaptic sympathetic blockade with bretylium tosylate and/or with local applications of L-Nitro-Arginine Methyl Ester (L-NAME) without evidence of any synergistic effect. Therefore, the neurogenic support of vasodilation appears to require the serial production of nitric oxide. The role of this vasodilatory pathway in constraining cutaneous vasoconstriction during whole-body cooling has not been investigated.
Perspectives and significance
NPY is now understood to be an important neurotransmitter in the control and regulation of skeletal muscle vasculature tone. 
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